Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
GEIS 2013 guidelines for gastrointestinal sarcomas (GIST).
Poveda A, del Muro XG, López-Guerrero JA, Martínez V, Romero I, Valverde C, Cubedo R, Martín-Broto J. Poveda A, et al. Among authors: del muro xg. Cancer Chemother Pharmacol. 2014 Nov;74(5):883-98. doi: 10.1007/s00280-014-2547-0. Epub 2014 Sep 6. Cancer Chemother Pharmacol. 2014. PMID: 25193432 Free PMC article. Review.
Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study.
Maurel J, López-Pousa A, Calabuig S, Bagué S, Del Muro XG, Sanjuan X, Rubió-Casadevall J, Cuatrecasas M, Martinez-Trufero J, Horndler C, Fra J, Valverde C, Redondo A, Poveda A, Sevilla I, Lainez N, Rubini M, García-Albéniz X, Martín-Broto J, de Alava E. Maurel J, et al. Among authors: del muro xg. Clin Sarcoma Res. 2016 Jun 29;6:10. doi: 10.1186/s13569-016-0050-6. eCollection 2016. Clin Sarcoma Res. 2016. PMID: 27358721 Free PMC article.
Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib.
Joensuu H, Blay JY, Comandone A, Martin-Broto J, Fumagalli E, Grignani G, Del Muro XG, Adenis A, Valverde C, Pousa AL, Bouché O, Italiano A, Bauer S, Barone C, Weiss C, Crippa S, Camozzi M, Castellana R, Le Cesne A. Joensuu H, et al. Among authors: del muro xg. Br J Cancer. 2017 Oct 24;117(9):1278-1285. doi: 10.1038/bjc.2017.290. Epub 2017 Aug 29. Br J Cancer. 2017. PMID: 28850565 Free PMC article. Clinical Trial.
Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.
Maurel J, López-Pousa A, de Las Peñas R, Fra J, Martín J, Cruz J, Casado A, Poveda A, Martínez-Trufero J, Balañá C, Gómez MA, Cubedo R, Gallego O, Rubio-Viqueira B, Rubió J, Andrés R, Sevilla I, de la Cruz JJ, Del Muro XG, Buesa JM. Maurel J, et al. Among authors: del muro xg. J Clin Oncol. 2009 Apr 10;27(11):1893-8. doi: 10.1200/JCO.2008.19.2930. Epub 2009 Mar 9. J Clin Oncol. 2009. PMID: 19273704 Clinical Trial.
Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy.
Houédé N, Locker G, Lucas C, Parra HS, Basso U, Spaeth D, Tambaro R, Basterretxea L, Morelli F, Theodore C, Lusuardi L, Lainez N, Guillot A, Tonini G, Bielle J, Del Muro XG. Houédé N, et al. Among authors: del muro xg. BMC Cancer. 2016 Sep 23;16(1):752. doi: 10.1186/s12885-016-2782-3. BMC Cancer. 2016. PMID: 27664126 Free PMC article.
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG; GRID study investigators. Demetri GD, et al. Lancet. 2013 Jan 26;381(9863):295-302. doi: 10.1016/S0140-6736(12)61857-1. Epub 2012 Nov 22. Lancet. 2013. PMID: 23177515 Free PMC article. Clinical Trial.
Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias--a study of the Spanish group for research on sarcomas (GEIS).
Maurel J, Buesa J, López-Pousa A, del Muro XG, Quintana MJ, Martín J, Casado A, Martínez-Trufero J, de Las Peñas R, Balañá C. Maurel J, et al. Among authors: del muro xg. J Surg Oncol. 2004 Oct 1;88(1):44-9. doi: 10.1002/jso.20131. J Surg Oncol. 2004. PMID: 15384088
Sarcomas with spindle cell morphology.
Collini P, Sorensen PH, Patel S, Blay JY, Issels RD, Maki RG, Eriksson M, del Muro XG. Collini P, et al. Among authors: del muro xg. Semin Oncol. 2009 Aug;36(4):324-37. doi: 10.1053/j.seminoncol.2009.06.007. Semin Oncol. 2009. PMID: 19664493 Review.
Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma.
Puente J, Laínez N, Dueñas M, Méndez-Vidal MJ, Esteban E, Castellano D, Martinez-Fernández M, Basterretxea L, Juan-Fita MJ, Antón L, León L, Lambea J, Pérez-Valderrama B, Vázquez S, Suarez C, Del Muro XG, Gallardo E, Maroto JP, Samaniego ML, Suárez-Paniagua B, Sanz J, Paramio JM; SOGUG (Spanish Oncology Genitourinary Group). Puente J, et al. Among authors: del muro xg. Oncotarget. 2017 May 2;8(18):30410-30421. doi: 10.18632/oncotarget.16494. Oncotarget. 2017. PMID: 28423742 Free PMC article.
49 results